Research area
Cell & Gene Therapy
Therapeutic cells, gene-based treatments and biological regeneration, including engineered immune cells for cancer.
-
Evidence date ·What have CAR-iNKT cells done in patients, and what stands in the way?
Review or Meta-AnalysisSmall patient studies found CAR-iNKT cells in tumors and recorded some responses; lasting benefit and reliable production remain unproven.
-
Evidence date ·Could engineered immune cells help treat breast cancer?
Review or Meta-AnalysisThe review explains how CAR-T cells are designed and why breast tumors pose added hurdles. Its discussion of trials does not establish clinical benefit.
-
Evidence date ·What would engineered immune cells have to overcome inside a breast tumor?
Review or Meta-AnalysisA 2025 review examines how uneven tumor markers and dense tissue may hinder CAR-T cells in breast cancer. Early patient reports have not established lasting benefit.
-
Evidence date ·What could engineered immune cells safely target in aging and Alzheimer’s?
Review or Meta-AnalysisA 2025 review describes senescent-cell targeting in animals and amyloid removal by engineered macrophages in mice. Human benefit remains untested.
-
Evidence date ·Helping transplanted stem cells work in an inflamed osteoarthritis joint
Review or Meta-AnalysisA 2025 review compares natural compounds paired with stem cells in osteoarthritis models. Human evidence for these combinations remains limited and mixed.
-
Evidence date ·Can stem-cell-grown natural killer cells become dependable cancer treatments?
Review or Meta-AnalysisA review examines an early lymphoma result for stem-cell-derived natural killer cells. Tumor access, consistent production and lasting benefit remain uncertain.
-
Evidence date ·How reprogrammed adult cells reveal aging-related disease—and what repair would take
Review or Meta-AnalysisReprogrammed patient cells can form neurons and lung cells to model Alzheimer’s and telomere-related lung disease. Tissue repair would require safe, mature cells.
-
Evidence date ·Approved BCMA-targeting CAR T therapies can delay myeloma progression, but relapse remains possible
Review or Meta-AnalysisIn separate randomized trials, two BCMA CAR T therapies delayed myeloma progression and improved responses versus standard care. Relapse and serious side effects remain.
-
Evidence date ·Why researchers are engineering a different immune cell for solid tumors
Review or Meta-AnalysisThe January 2025 review explains how CAR-iNKT cells pair native lipid recognition with an added tumor-targeting receptor. Patient benefit remains unproven.
-
Evidence date ·Can researchers make more liver cells for repair?
Review or Meta-AnalysisResearchers are testing ways to redirect cells toward liver roles, but cell stability, targeted delivery, and human translation remain unresolved.